Key result
Elevated sLOX-1 is linked to ~49% higher odds of unfavorable outcomes after recurrent stroke.
Observational (n=266)
Answers are grounded in this paper and cite their sources.
Explores sLOX-1 as a new prognostic marker in recurrent stroke patients, suggesting distinct risk factors for stroke types.
Several clinical parameters and biomarkers have been proposed as prognostic markers for stroke. However, it has not been clarified whether the risk factors affecting the prognosis of patients with recurrent and first-ever stroke are similar. In this study, we aimed to explore the relationship between soluble lectin-like oxidized low-density lipoprotein receptor 1 (sLOX-1) levels and the prediction of the functional outcome in patients with recurrent and first-ever stroke. A total of 266 patients with recurrent and first-ever stroke, who underwent follow-up for 3 months, were included in this study. Plasma samples were collected within 24 h after onset. The results showed that biomarkers for the prognosis of patients with recurrent stroke were different from that of those with first-ever stroke. sLOX-1 levels were correlated with modified Rankin Scale scores of patients with recurrent stroke alone ( <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mi>r</a:mi> <a:mo>=</a:mo> <a:mn>0.3232</a:mn> </a:math> , <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"> <c:mi>p</c:mi> <c:mo>=</c:mo> <c:mn>0.001</c:mn> </c:math> ). sLOX-1 levels were also associated with an increased risk of unfavorable outcomes in patients with recurrent stroke with an adjusted odds ratio of 1.489 (95% confidence interval, 1.204–1.842, <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"> <e:mi>p</e:mi> <e:mo><</e:mo> <e:mn>0.0001</e:mn> </e:math> ). Combining the risk factors showed greater accuracy for prognosis, yielding a sensitivity of 93.2% and a specificity of 75%, with an area under the curve of 0.916, evaluated by the receiver operating characteristic curve. These findings suggest that the diagnosis and prognosis are different between patients with recurrent stroke and those with first-ever stroke, and sLOX-1 level is an independent prognostic marker in patients with recurrent stroke.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2021) conducted an observational in Recurrent and first-ever stroke (n=266). sLOX-1 levels vs. Lower sLOX-1 levels was evaluated on Unfavorable functional outcome (OR 1.489, 95% CI 1.204-1.842, p=<0.0001). Elevated sLOX-1 levels were associated with an increased risk of unfavorable functional outcomes in patients with recurrent stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: